Severe Covid-19 disease is associated with well-documented comorbidities, like age, cardiovascular and respiratory diseases. However, SARS-CoV-2 infections in children has been described as relatively benign, resulting in minimal hospitalizations and a low mortality rate. Since the beginning of the pandemic, hospitals within Europe and North America have recorded cases of multisystem inflammatory disease in pediatric patients with or previously exposed to Covid-19. Early descriptions have included a wide variety of clinical symptoms, which overlap with other inflammatory conditions like Kawasaki disease and toxic shock syndrome. Nevertheless, MIS-C is a unique condition in which a significant proportion of patients are affected by severe or fatal disease.